En Carta Diagnostics

Loading...

About En Carta Diagnostics

En Carta Diagnostics is a deeptech start-up developing rapid Point-of-Care molecular diagnostics kits. It focuses on the early diagnosis of Lyme disease as a first application. The company operates a patented molecular diagnostics platform with an exclusive worldwide license. Founded in 2022, En Carta has built five prototypes, published ten papers in scientific journals on the proof of concept on pathogens including Zika, chikungunya, malaria, Ebola and typhoid, and secured a commercial contract with a digital healthcare leader.

Located in Paris, France, En Carta Diagnostics is incubated at Paris Biotech Santé, PC’UP and 50 Partners Santé.

Its scientific team members also received a $17.7M DARPA project award in 2023 and collaborate with an extensive network of research institutes in Latin America.

Facts about En Carta Diagnostics
  • Founding: 2022
  • Focus : Manufacturer
  • Employees: 1-10
  • Industry : Diagnostics

Product portfolio of En Carta Diagnostics

Here you will find En Carta Diagnostics

See the theme worlds for related content